An intravenous administration of (D-ala2, met5)-enkephalinamide (DALA) caused a significant elevation of plasma ACTH and corticosterone at 10 to 20 min after injection in unanesthetized freely moving rats. An intraperitoneal administration of cyproheptadine tended to reduce plasma ACTH and corticosterone levels at 60 min after injection, but it did not attenuate the DALAinduced ACTH and corticosterone elevation. A large dose of naloxone (1-10 mg/kg body weight) caused a significant elevation in plasma corticosterone, but naloxone at 10 mg/kg body weight reduced the basal ACTH level and DALA-induced ACTH elevation. When both DALA and naloxone were injected, the steroidogenic effect was attenuated.
Since the discovery of endogenous opioid peptides in the brain and pituitary, evidence has been accumulating that they play an important role in regulating pituitary-adrenal function. However, the controversy continues on the role of the opioid peptides in hypothalamo-pituitary-adrenocortical activity. Some investigators reported a stimulatory role of endogenous opioid peptides in ACTH secretion (George & Way, 1979; Gibson et al., 1979; Buckingham & Cooper, 1984) , while others reported that opioid peptides tonically inhibited ACTH secretion (Stubbs et al., 1978; Del Pozo et al., 1980; Gaillard et al., 1981) . Intravenous administrations of enkephalin analogues were reported to inhibit ACTH and cortisol secretion in man, while it stimulated plasma ACTH and corticosterone levels in rats (Ferri et al., 1980; De Souza & Van Loon, 1982) .
There is also controversy about the effects of naloxone, an opiate antagonist, on ACTH and corticosteroid secretion. A high dose of naloxone elevated circulating ACTH (Volavka et al., 1979; Morley et al., 1980) , whereas low doses were ineffective (Spiler & Molith, 1980 Effect of naloxone on ACTH and corticosterone secretion Naloxone at 0.2 and 1.0 mg/kg body weight did not cause a statistically significant change in plasma ACTH, whereas naloxone at 5 or 10 mg/kg body weight lowered the plasma ACTH level at 40 min (Fig. 2 ) and 50 min (Fig. 3) after injection. Plasma corticosterone showed a significant rise after naloxone (1.0 and 10 mg/kg body weight) administration (Fig. 2) . Naloxone at 5 mg/kg body weight completely blocked the DALA-induced ACTH rise (Fig. 3) . In rats that received both naloxone and DALA, the plasma corticosterone level at 20 min after naloxone injection was lower than in only naloxone or DALA injected rats (Fig.  3) .
Effect of DALA and naloxone on ACTH release in pituitary cell cultures Neither DALA at 1-1,000 ng/ml nor naloxone at 10-7 M-10-4 M affected the basal ACTH release or the CRF-induced ACTH release in pituitary cell cultures (Fig.  4,Fig. 5 ).
Discussion
We had already observed that an intrathird ventricular administration of DALA potentiated a mild stress-induced ACTH and corticosterone rise. The present investigation showed that an intravenous DALA administration caused a rise in ACTH and corticosterone, but it did not stimulate an ACTH release from pituitary cells in in vitro experiments.
These results indicate that DALA acts at the extra-hypophyseal level to stimulate ACTH secretion. There is, however, substantial evidence to indicate that a number of opioid precursors alter basal or stimulated adrenal steroidogenesis directly in vitro (Pedersen & Brownie, 1980; Racz et al., 1980; Matsuoka et al., 1980) . Therefore, peripherally administered DALA may act at the extra-hypophyseal level to stimulate corticosterone secretion.
On the other hand, methionine-enkephalin analogue (Damme-FK 38-824) caused a suppression of ACTH and cortisol in man (Stubbs et al., 1978; Del Pozo et al., 1980; Grossman & Besser, 1982) . Although the discrepancy between man and laboratory animals in the methionine-enkephalin analogue effect on the pituitary-adrenal system is hard to explain, it may be ascribed to a species difference.
Several investigators have shown that not only opioids but also naloxone, the specific antagonist of morphine receptors, stimulates adrenal steroidogenesis. Some investigators (Volavka et al., 1979; Gibson et al., 1979; Siegal et al., 1982; Eisenberg, 1984) suggested that naloxone acts directly on the central nervous system regulating ACTH secretion, but others reported that naloxone acts directly on the adrenal cortex (Lymangrover et al., 1981; Jezova, 1985) . Our present results have shown that naloxone stimulates corticosterone secretion without elevating ACTH. The results suggest that naloxone has a direct stimulatory effect on corticosterone secretion or it stimulates corticosterone-stimulating factors other than ACTH.
The mechanism by which naloxone stimulates corticosterone secretion is not clear. Lymangrover et al.(1981) reported the direct effect of both methionine-enkephalin and naloxone on adrenal steroid secretion. The most prominent effect was the potentiation of the steroidogenic action of ACTH by interaction with one or more relatively nonspecific membrane receptors which are distinctly different from the ACTH receptor. They also suggested a mechanism which involves a change in membrane permeability to one or more ions, resulting in an optimal intracellular ion concentration. Although both DALA and naloxone showed a steroidogenic effect, the response was attenuated when both were given to rats. The results indicate that they act antagonistically on adrenal cortex cells.
The present investigation showed that a large dose of naloxone rather lowered the plasma ACTH level. An elevated level of plasma corticosterone may partly explain the reduction in plasma ACTH. However, naloxone at 1 mg/kg body weight did not lower the plasma ACTH level although it elevated the plasma corticosterone level. Our results showed that naloxone had no direct effect on the release of ACTH from pituitary cells. Therefore, it is also possible that naloxone lowered the plasma ACTH level by blocking the endogenous opioid effects at the hypothalamic level. The discrepancy between the effects of naloxone on plasma ACTH level in our study and others (Siegel et al., 1982; Jezova 1985) may be ascribed to experimental conditions. In our experiments, blood was sampled with a jugular cannula in unanesthetized freely moving rats, without additional stress. Siegel et al., (1982) injected naloxone intraperitoneally and collected blood samples after decapitation. Jezova (1985) also injected naloxone intraperitoneally although he used indwelling catheters.
Opioid peptides stimulate prolactin and GH secretion via a serotonergic mechanism (Spampinato et al., 1979) . A serotonergic mechanism has been reported to stimulate ACTH secretion (Jones et al., 1976; Meyer et al., 1978; Hashimoto et al., 1982) . Our results here show that a serotonergic mechanism may be involved in sustaining the basal plasma level but it was not involved in the DALA-induced ACTH stimulation.
In summary, the present investigation suggests that the stimulatory effect of DALA on the hypothalamo-pituitary-adrenal system is mediated by stimulating the secretion of CRF or other ACTH secretagogues and that the stimulatory effect of naloxone on steroidogenesis acts at the adrenal gland or is mediated by stimulating other corticosteronestimulating factors.
